Surgery represents the primary treatment modality. Chemotherapy may be ineffective, but checkpoint inhibitors and BRAF and MEK inhibitors have been recently tested in<unk> s. Less than 10% of<unk> s have BRAF-mutations. Therefore BRAF-inhibitors play only a minor role in<unk> s (unlike in skin<unk> s). However, a recent study has shown that checkpoint inhibitors (inkluding CTLA-4 inhibitors and PD-1 inhibitors) are effective in the treatment of advanced vulvovaginal<unk> s.
Vaginal melanoma
Cutaneous endometriosis
Vaginal cancer
Squamous-cell carcinoma of the vagina
Pyometra
Vulvar cancer
Hidradenoma
Breast cyst